Alessio Nicola, Stellavato Antonietta, Aprile Domenico, Cimini Donatella, Vassallo Valentina, Di Bernardo Giovanni, Galderisi Umberto, Schiraldi Chiara
Department of Experimental Medicine, Luigi Vanvitelli Campania University, Naples, Italy.
Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, Temple University, Philadelphia, PA, United States.
Front Cell Dev Biol. 2021 Apr 12;9:641529. doi: 10.3389/fcell.2021.641529. eCollection 2021.
Mesenchymal stromal cells (MSCs) are currently used for cartilage cell therapy because of their well proven capacity to differentiate in chondrocytes. The advantage of MSC-based therapy is the possibility of producing a high number of chondrocytes for implants. The transplant procedure, however, has some limitations, since MSCs may produce non-functional chondrocytes. This limit has been challenged by cultivating MSC in media with hydrogels containing hyaluronic acid (HA), extractive chondroitin sulfate (CS), or bio-fermentative unsulphated chondroitin (BC) alone or in combination. Nevertheless, a clear study of the effect of glycosaminoglycans (GAGs) on chondrocyte differentiation is still lacking, especially for the newly obtained unsulfated chondroitin of biotechnological origin. Are these GAGs playing a role in the commitment of stem cells to chondrocyte progenitors and in the differentiation of progenitors to mature chondrocytes? Alternatively, do they have a role only in one of these biological processes? We evaluated the role of HA, CS, and - above all - BC in cell commitment and chondrocyte differentiation of MSCs by supplementing these GAGs in different phases of cultivation. Our data provided evidence that a combination of HA and CS or of HA and BC supplemented during the terminal differentiation and not during cell commitment of MSCs improved chondrocytes differentiation without the presence of fibrosis (reduced expression of Type I collagen). This result suggests that a careful evaluation of extracellular cues for chondrocyte differentiation is fundamental to obtaining a proper maturation process.
间充质基质细胞(MSCs)因其已被充分证实的向软骨细胞分化的能力,目前被用于软骨细胞治疗。基于MSC的治疗的优势在于有可能为植入物生产大量软骨细胞。然而,移植程序存在一些局限性,因为MSCs可能产生无功能的软骨细胞。通过在含有透明质酸(HA)、硫酸软骨素提取物(CS)或生物发酵未硫酸化软骨素(BC)的水凝胶培养基中单独或联合培养MSCs,这一局限性受到了挑战。尽管如此,对于糖胺聚糖(GAGs)对软骨细胞分化的影响仍缺乏明确的研究,尤其是对于新获得的生物技术来源的未硫酸化软骨素。这些GAGs在干细胞向软骨细胞祖细胞的定向分化以及祖细胞向成熟软骨细胞的分化过程中是否发挥作用?或者,它们仅在这些生物学过程之一中起作用?我们通过在培养的不同阶段添加这些GAGs,评估了HA、CS以及最重要的BC在MSCs的细胞定向分化和软骨细胞分化中的作用。我们的数据表明,在MSCs的终末分化而非细胞定向分化阶段添加HA和CS或HA和BC的组合,可在无纤维化(I型胶原蛋白表达降低)的情况下改善软骨细胞分化。这一结果表明,仔细评估软骨细胞分化的细胞外信号对于获得适当的成熟过程至关重要。